• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Neuropsychopharmacology >Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus
【2h】

Selective Serotonin Reuptake Inhibitors Affect Neurobehavioral Development in the Human Fetus

机译：选择性5-羟色胺再摄取抑制剂影响人类胎儿的神经行为发育。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The aim of this prospective study was to investigate whether selective serotonin reuptake inhibitors (SSRIs) utilized by pregnant women influence fetal neurobehavioral development. In this observational study we investigated developmental milestones of fetal behavior during the pregnancy of women with psychiatric disorders who took SSRIs throughout gestation (medicated group; n=96) or who had discontinued medication early in gestation or before conception (unmedicated group; n=37). Healthy unexposed fetuses of women without mental disorders comprised the control group (n=130). Ultrasonographic observations of fetal behavior were made three times in pregnancy (T1–T3). Effects of SSRIs were studied over a wide range of dosages (low, standard, or high) and for different drug types. Fetuses exposed to standard or high SSRI dosages compared with control, unmedicated, or low-medicated fetuses showed significantly increased motor activity at the beginning (T1) and end of the second trimester (T2). They particularly exhibited disrupted emergence of non-rapid eye movement (non-REM; quiet) sleep during the third trimester, characterized by continual bodily activity and, thus, poor inhibitory motor control during this sleep state near term (T3). The SSRI effects on the fetus were dose related, but independent of SSRI type. The results demonstrate changes in fetal neurobehavioral development associated with standard and high SSRI dosages that are observable throughout gestation. A first-choice SSRI type was not apparent. Bodily activity at high rate during non-REM sleep in SSRI-exposed fetuses is an abnormal phenomenon, but its significance for postnatal development is unclear.
机译：这项前瞻性研究的目的是调查孕妇使用的选择性5-羟色胺再摄取抑制剂（SSRI）是否会影响胎儿神经行为的发育。在这项观察性研究中，我们调查了患有精神疾病的妇女在整个妊娠期间服用SSRIs（药物治疗组； n = 96）或在妊娠早期或受孕前中止药物治疗（非药物治疗组； n = 37）的胎儿行为发展的里程碑。 ）。对照组（n = 130）为未患精神疾病的健康未暴露胎儿。在怀孕期间（T1-T3）进行了三次胎儿行为的超声检查。在各种剂量（低，标准或高）和不同药物类型下研究了SSRI的作用。与对照组，未用药或低用药的胎儿相比，暴露于标准或高SSRI剂量的胎儿在孕早期（T1）和孕中期（T2）结束时显示出明显的运动活动。他们尤其表现出在妊娠中期不快速的眼动睡眠（非快速眼动；安静）睡眠的出现，其特征是持续的身体活动，因此在短期（T3）的睡眠状态下抑制运动控制能力差。 SSRI对胎儿的影响与剂量有关，但与SSRI类型无关。结果表明，在整个妊娠期均可观察到与标准和高SSRI剂量相关的胎儿神经行为发育的变化。首选SSRI类型不明显。 SSRI暴露的胎儿在非快速眼动睡眠期间的身体活动率很高，这是一种异常现象，但其对产后发育的意义尚不清楚。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号